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Australasian Malignant PLeural Effusion
(AMPLE)‑3 trial: study protocol for a multi‑centre
randomised study comparing indwelling
pleural catheter (±talc pleurodesis)
versus video‑assisted thoracoscopic surgery
for management of malignant pleural effusion
Deirdre B. Fitzgerald1,2,3 , Calvin Sidhu1,3,4, Charley Budgeon5, Ai Ling Tan3, Catherine A. Read3,
Benjamin C. H. Kwan6,7, Nicola Ann Smith8, Edward T. Fysh2,9, Sanjeevan Muruganandan10, Tajalli Saghaie11,12,
Ranjan Shrestha13, Arash Badiei14,15, Phan Nguyen14,15, Andrew Burke16,17, John Goddard18,19,
Morgan Windsor20, Julie McDonald21, Gavin Wright22, Kasia Czarnecka23, Parthipan Sivakumar24,
Kazuhiro Yasufuku23, David J. Feller‑Kopman25, Nick A. Maskell26, Kevin Murray5 and Y. C. Gary Lee1,2,3*

Abstract
Introduction: Malignant pleural effusions (MPEs) are common. MPE causes significant breathlessness and impairs
quality of life. Indwelling pleural catheters (IPC) allow ambulatory drainage and reduce hospital days and re-interven‑
tion rates when compared to standard talc slurry pleurodesis. Daily drainage accelerates pleurodesis, and talc instil‑
lation via the IPC has been proven feasible and safe. Surgical pleurodesis via video-assisted thoracoscopic surgery
(VATS) is considered a one-off intervention for MPE and is often recommended to patients who are fit for surgery. The
AMPLE-3 trial is the first randomised trial to compare IPC (±talc pleurodesis) and VATS pleurodesis in those who are fit
for surgery.
Methods and analysis: A multi-centre, open-labelled randomised trial of patients with symptomatic MPE, expected
survival of ≥ 6 months and good performance status randomised 1:1 to either IPC or VATS pleurodesis. Participant
randomisation will be minimised for (i) cancer type (mesothelioma vs non-mesothelioma); (ii) previous pleurodesis (vs
not); and (iii) trapped lung, if known (vs not). Primary outcome is the need for further ipsilateral pleural interventions
over 12 months or until death, if sooner. Secondary outcomes include days in hospital, quality of life (QoL) measures,
physical activity levels, safety profile, health economics, adverse events, and survival. The trial will recruit 158 partici‑
pants who will be followed up for 12 months.
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Ethics and dissemination: Sir Charles Gairdner and Osborne Park Health Care Group (HREC) has approved the study
(reference: RGS356). Results will be published in peer-reviewed journals and presented at scientific meetings.
Discussion: Both IPC and VATS are commonly used procedures for MPE. The AMPLE-3 trial will provide data to help
define the merits and shortcomings of these procedures and inform future clinical care algorithms.
Trial registration: Australia New Zealand Clinical Trial Registry ACTRN12618001013257. Registered on 18 June 2018.
Protocol version: Version 3.00/4.02.19
Keywords: Pleural effusion, Indwelling pleural catheter, Malignant, Video-assisted thoracoscopic surgery,
Randomised controlled trial

Introduction
Malignant pleural effusion (MPE) affects over 10,000
Australians and an estimated 5 million people worldwide
each year [1]. MPE can complicate most cancers, including 30% of breast and lung cancers and more than 90%
of malignant pleural mesotheliomas [2]. The resultant
breathlessness is disabling and significantly impairs quality of life. Key goals of management are to relieve breathlessness and enable physical activity while minimising
interventions and time spent in hospital, in a cost-effective manner. MPE is associated with a major healthcare
burden with annual care costs of over $5 billion in the
USA alone [3].
MPE usually indicates incurable cancer with a variable
prognosis from days to years; median survival can be as
short as four months in lung carcinomas and 12 months
in mesothelioma [4–6]. Prognosis depends on multiple
factors including performance status and tumour type
[4]. Younger, fitter patients, with a prognostically favourable tumour type can be expected to have a significantly
longer survival than those with comorbidities and less
favourable cancers and, therefore, may warrant significantly different MPE management approaches. A definitive procedure to prevent re-accumulation of effusion
post-drainage is typically required to reduce repeated
interventions, hospitalisations, and complications. Various treatments with definitive intent of fluid control are
available but each has its advantages and limitations.
Surgical pleurodesis is viewed by many clinicians
as a one-off intervention with high long-term success
rates. Video-assisted thoracoscopic surgery (VATS) has
replaced open thoracotomy as the preferred surgical procedure for pleurodesis [7]. If successful, VATS pleurodesis can provide lifelong freedom from the effusion and is
the first-line therapy in many institutions worldwide [8].
Reported success rates of 68 to 100% are based mainly on
retrospective or single-centre studies [9–12]. One retrospective review of mesothelioma found a re-intervention
rate of 32% in the subgroup of patients who underwent
VATS pleurodesis at a median of 30 days post-surgery,
which was not significantly different from the bedside

talc slurry pleurodesis subgroup [13]. Disadvantages of
VATS include complications such as fever, pneumonia,
and prolonged air leak, occurring in up to 28% of cases
[9–12, 14–20]. Post-VATS intercostal neuralgia is also
a common long-term complication affecting 25% of
patients [21]. VATS pleurodesis requires a median of 5.8
to 10.3 days of hospital stay [12, 15]. The frequent need
for general anaesthesia and single lung ventilation also
limit the availability of the procedure to patients who are
considered fitter and have longer expected survival.
The limitations of surgical pleurodesis have encouraged
the development of alternative approaches. Indwelling
pleural catheter (IPC) is an ambulatory drainage device
for patients with MPE that can be managed on an outpatient basis. A tunnelled catheter is sited and patients
(and/or their carers) are educated in home drainage.
Multiple prospective studies in the past decade have
firmly established IPC as a strong alternative to talc
slurry pleurodesis [22, 23]. IPC offers a significant reduction in the need for further interventions for drainage of
symptomatic pleural fluid. In prior trials, only 2–6% of
IPC-treated patients required further pleural drainages
(compared with over 20% in conventional talc pleurodesis) [9, 22, 23]. IPC is also associated with a reduction in
hospital days vs talc slurry pleurodesis [22–24]. IPC provides effective palliation in the presence of trapped lung,
a cohort in whom talc slurry pleurodesis fails due to lack
of visceral and parietal pleural apposition [25, 26].
Spontaneous pleurodesis occurs in 40–51% of patients
with IPC at a median of 59.0–80.5 days, allowing removal
of the IPC [6, 23, 24, 27], especially if the IPC is drained
aggressively (e.g., daily) [28, 29]. Talc slurry instillation via IPC has been shown to be safe and feasible with
pleurodesis success rates of > 90% in two prospective
case series [30, 31]. The feasibility of this combined (IPC
+ talc) approach was confirmed in a randomised controlled trial (RCT) [32]. Combining IPC with talc pleurodesis and daily drainage may improve outcomes. IPC
has its own unique range of complications such as infection (~ 5%) [33, 34], symptomatic loculations (8–13%)
[6, 27, 35], and catheter tract metastases (10%) [36]. IPC
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care can be time consuming and, for patients with better prognoses, may become a burden. IPC also requires
ongoing consumables that may result in reduced costeffectiveness with longer survival [37–39].
Clinical equipoise exists regarding the optimal treatment for MPE, and there is significant dichotomy worldwide. Due to a paucity of high-quality data, decisions
are often based on clinician bias and available resources.
VATS pleurodesis is conventionally regarded as the optimal approach to provide long-term control of MPE in
patients who are fit for surgery. While the role of IPC
over bedside talc slurry pleurodesis in the MPE population has been proven, RCTs of IPC (± pleurodesis) to
date have investigated patients with advanced cancers,
approximately one third of study patients dying within
3 months. Studies of IPC in patients with better performance status and predicted survival, who would also be
suitable for VATS pleurodesis, are overdue. Whether IPC
combined with talc pleurodesis, and daily drainage would
be superior to VATS pleurodesis is unknown. A prospective randomised comparison is required to answer this
question.

Patients with a performance status ≥ 2 may be included
if it is felt that removal of the pleural fluid would improve
their performance status to 1 or better. MPE is defined as
either histocytologically proven pleural malignancy or an
exudative effusion with no other cause in a patient with
known primary extra-pleural malignancy.

Methods

Interventions
VATS arm

Study design

The Australian Malignant PLeural Effusion (AMPLE)
trial-3 is a multi-centre, open-labelled, randomised (trial
entry) study to determine the comparative efficacy of two
frequently applied interventions for MPE (VATS or IPC)
in improving patient-related clinical outcomes.
Study setting, participant screening, selection,
and recruitment

This trial will be conducted at tertiary centres across
Australia, New Zealand, Canada, and the UK. Currently
involved institutions are listed in the ethics section. The
full list of enrolling sites will be updated regularly on
the trial registration website (URL: ACTRN1261800101
3257). The site investigator or designated research staff
will screen patients in both inpatient and outpatient settings. Consecutive eligible patients will be offered trial
entry and screening logs will be kept.
Research teams at each site will be contacted regularly
by the lead site to discuss hurdles to recruitment. Enrolment and screening logs, including reasons for noninclusion, will be maintained and de-identified logs will
be sent to the lead site monthly.
Inclusion criteria

Patients with symptomatic MPE that requires definitive intervention, with a predicted survival of more than
6 months and an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 to 1 will be included.

Exclusion criteria

Exclusion criteria includes age < 18 years; unfit to undergo
surgical procedure (American Society of Anaesthesiology Score ≥ 4); significant loculations likely to preclude
effective drainage via IPC; pleural infection; chylothorax;
pregnancy or lactation; uncorrectable bleeding diathesis;
and previous ipsilateral lobectomy/pneumonectomy and
inability to consent or comply with the protocol.
Informed consent

Potential participants will be provided with verbal information and the participant information and consent
form (PICF) to read by a member of the research team.
They will be given time to ask questions and to discuss
the study with family/carers and their GP.

Participants randomised to the VATS arm will undergo
surgery within two weeks of randomisation. VATS is
usually performed in an operating theatre, using either
general anaesthesia or sedation. The pleural fluid will be
removed, and adhesions can be divided. Assessment of
lung re-expansion will be performed intra-operatively. If
lung re-expansion is adequate (as judged by the operating surgeon), a variety of techniques may be employed
to induce pleurodesis, including, but not limited to, talc
poudrage and mechanical abrasion. Decortication may
be performed if deemed appropriate and feasible. A chest
drain (non-IPC) will be left in situ after the surgery. Postoperative care will be performed as per local practice.
IPC arm

IPCs will be inserted as per local protocols. If full lung
expansion (see Trapped Lung SOP, Additional file 1) is
achieved after drainage of the effusion (typically assessed
1 day post-insertion), sterile talc (4–5 g, graded) will be
instilled as a slurry via the IPC, and subsequent management (e.g., use of suction) will follow local protocols for
talc slurry pleurodesis at each site. Daily drainage with
suction bottles will then be performed for 7 to 10 days
after talc instillation until outpatient review. Successful
development of pleurodesis is defined as fluid output of
less than 50 ml on three consecutive drainage attempts
via IPC without evidence of fluid accumulation on
imaging. The IPC can be removed when pleurodesis is
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achieved. In the case of ongoing pleural fluid production
and drainage via the IPC, daily drainage can continue or
be adjusted to a symptom-guided drainage regimen as
determined by the treating team.
If the lung does not fully expand following complete
evacuation of pleural fluid (see Trapped Lung SOP, Additional file 1), the participant will be discharged on a daily
drainage regimen to allow the best chance of full lung reexpansion, which will be assessed at outpatient followup. In the event of full lung expansion (≥ 75% pleural
apposition) in association with ongoing fluid production,
talc instillation via IPC can be considered (as described
above) and followed by daily drainage and review at
7–10 days after the attempted pleurodesis. If the lung
remains trapped, further drainage will follow a symptomguided drainage regimen. At any time, if the output is
< 50 ml/drainage on three consecutive drainage attempts
at least 24 hapart, with no evidence of symptomatic fluid
accumulation, the IPC can be removed.
Standard care and follow‑up

Participants in both arms will be managed by their own
clinical teams and receive all other usual medical treatment (including chemotherapy and radiotherapy). All
participants and carers will have access to the research
team should any concerns arise. This cohort will remain
under the continued care of a physician or thoracic surgeon following trial completion.
Participants are advised prior to enrolment that they
are free to withdraw from the trial at any time if they so
wish. Following randomisation, changes to the intervention plan may be made at the discretion of the treating
physician or due to participant request.
Strategies to improve adherence to interventions
and participant retention

Potential participants, as part of the informed consent
process, will have the study procedures and visit plan discussed in detail. An emphasis will be placed on the need
for attendance at all study visits. Where participants do
not attend planned study visits, the research team will
make contact and book an unscheduled visit if required.
Outcomes

Data will be collected by the site investigators from the
participant at follow-up visits (see 16) and from their
hospital record.
Primary endpoint

The primary outcome is the need for an ipsilateral pleural intervention within 12 months of randomisation
for symptomatic recurrence of pleural effusion. Pleural intervention will be defined as an ipsilateral surgical
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procedure, chest drain insertion or thoracentesis with
therapeutic intent.
Secondary endpoints

a. Repeat ipsilateral pleural intervention including diagnostic aspiration, e.g., for the investigation of possible
infection will be identified as above
b. Time to symptomatic effusion recurrence will be
measured from the date of procedure, by performing
radiological investigations if the participant describes
worsening dyspnoea at a study visit. Recurrent effusion is defined as greater than 25% increase in opacification on chest x-ray (CXR) on the side of the intervention, and evidence of pleural fluid on ultrasound
c. All-cause and pleural-related hospital days will be
measured. Length of stay post-procedure and hospitalisation for any cause (except for elective admissions for chemotherapy) will be recorded for all participants post-enrolment until the end of follow-up
period or death. Admissions will be analysed as total
admission days (and number of episodes) and as
pleural-related admission days
d. Degree of breathlessness will be measured using
a 100-mm visual analogue scale (VAS), which is a
validated score of dyspnoea in MPE [23]. The VAS
is a 100 mm line anchored with “no breathlessness”
at 0 mm and “worst breathlessness imaginable” at
100 mm and will be done during the aforementioned
outpatient reviews. Two independent researchers will
measure all VAS scores and the mean score will be
calculated. Differences in scores of more than 3 mm
in both measurements will be repeated by the same
observers
e. Pain will be assessed using a 100-mm VAS with timing and measurement as for breathlessness
f. Quality of Life (QoL) will be measured using two
instruments, the EQ-5D-5L questionnaire and VAS
QoL, both employed as primary or secondary endpoints in previous RCTs [23, 40]. VAS QoL records
self-rated quality of life on a 100 mm line, anchored
with “best imaginable quality of life” at one end-point
and “worst imaginable quality of life” at the other.
QoL will be measured at each study visit
g. Physical activity patterns will be evaluated by a wellvalidated triaxial accelerometer (ActiGraph GT3X+,
Pensacola, FL, USA) providing an indication of functional status [41]. Standard data processing will be
applied and the weekly duration of low, moderate,
and vigorous-intensity physical activity determined
in accordance with established ranges. This will be
performed at the lead-site only
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Participant timeline

h. Adverse events will be recorded from time of enrolment until end of follow-up or death. An adverse
event is defined as any complication associated with
the IPC or VATS pleurodesis, including, but not limited to, pleural infection, cellulitis, pain, symptomatic
loculation +/− requirement of intrapleural fibrinolytics, tube blockage, catheter tract metastases,
parenchymal air leak, etc., and any peri/post-procedural complications such as prolonged air-leak, atelectasis, pneumonia, cardiovascular complications,
acute kidney injury, or drop in haemoglobin requiring transfusion
i. Economic analysis will be performed by obtaining
inpatient costs from the hospital. Outpatient pleural
care costs and equipment utilisation will be noted
(Western Australia only)
j. Overall survival will be recorded from date of enrolment to death or end of study follow-up

Baseline data will be collected once informed consent has
been obtained. Data collected will include demographics,
ASA, ECOG performance status, questionnaires (VAS
breathlessness, VAS QoL, VAS pain, EQ-5D-5L), comorbidities, malignancy type, stage and treatment, baseline
bloods (full blood picture, albumin, lactate dehydrogenase, C-reactive protein), baseline CXR findings, baseline
ultrasound thorax and pleural effusion data including
laboratory results and previous interventions.
The assigned intervention will be scheduled to occur
within 2 weeks of randomisation. Participants will be followed up between day 7 and 10 post-procedure, monthly
to 6 months, at 9 months, and at 12 months or death if
sooner (Table 1, Fig. 1). There will be a visit ‘window’ initially of ±3 days surrounding the early visits. Later visit
dates will have a larger visit window.
Sample size

This study will enrol 158 patients to detect a 5% reintervention rate in optimised IPC vs 25% reintervention rate

Table 1 Schedule of treatment for each visit and follow-up procedures
Study period
Pre-procedure

Post-procedure

Enrolment

Within 2/52

Days post-procedure

T-1

T0

D1

Clinical assessment

X

X

X

Bedside ultrasounda

X

Informed consent

X

Timepoint

Discharge

D7-10

Months
D28

2–6

9

12

Enrolment:

  Baseline data collection

X

  Blood testsb

X

  CXRc

X

Randomisation (IVRS)

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Interventions:
Drainage procedure (VATS or IPC)

X

Assessments:
Questionnaires (VAS QoL, dyspnoea, pain; EQ5D5L)

X

Logbook commencement

X

Logbook collection

X

Procedure-related data collection
ActiGraph to participant—lead site only

X
X

Assessment for pleurodesisd

a

X

X

X

X

X

X

X

X

X

Assessment for re-intervention

X

X

X

X

X

X

Adverse event review

X

X

X

X

X

X

Bedside ultrasound mandatory at baseline only

b

Blood tests to include FBC, albumin, LDH, and CRP

c

CXR mandatory at baseline, days 7–10, and months 1, 3, 6, 9, and 12

d

IPC arm only. Spontaneous pleurodesis is defined as < 50 ml drain output on 3 consecutive drainages at least 24 h apart
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Fig. 1 Study flow chart. MPE, malignant pleural effusion

in VATS (based on previous studies [13, 22, 23]). The sample size calculation was carried out using an anticipated
Fishers exact test to compare these proportions in each of
the two groups. With a 5% significance level and a power of
approximately 90%, we would need 75 patients per group
with an additional 4 patients per group to allow for dropouts (5% anticipated) giving a total of 158 patients. Withdrawal or loss to follow-up only occurred in 4.8% (7/146)
patients in our previous AMPLE-1 trial of MPE [22].
Randomisation and blinding

Participants will be randomly assigned (1:1) to either IPC
(with talc if suitable) or VATS pleurodesis. Randomisation will include minimisation for (i) cancer type (mesothelioma vs non-mesothelioma); (ii) previous pleurodesis
(vs not); and (iii) trapped lung, if known (vs not known).
The nature of the intervention means that investigators
and patients cannot be blinded to the treatment arms.
The National Health and Medical Research Council Clinical Trials Centre, Sydney, Australia, provides the randomisation setup via their automated telephone-based
interactive voice response services. Where possible,

data analysts will be blinded for analysis of the outcomes
although the very different profiles of treatment outcomes of the allocated treatments will make complete
blinding difficult.
Data management and safety

Data will be entered into a secure database and a system of data validation checks will be implemented and
applied. The accuracy of the data will be verified through
data monitoring and comparison to source documents.
Data entered will be checked by a second staff to ensure
accuracy.
All physical documentation will be stored in a secure
environment in line with the Australian Code for the
Responsible Conduct of Research for clinical trials and
local policy guidelines for research data archiving. All
procedures for the handling and analysis of data will
be conducted using GCP ICH guidelines, the National
Statement on Ethical Conduct in Human Research
(2007)—Updated May 2015, and local policies and procedures for the handling and analysis of data.
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Statistical plan

Sponsorship

Data will be analysed on an intention-to-treat basis and
per protocol basis. The primary outcome will be analysed using a Fisher’s exact test for comparing two proportions and subsequent logistic regression analyses
allowing adjustments for minimisation variables. A secondary analysis of the primary outcome will use a competing risks time to event analysis with the competing
risk of death. For the secondary outcomes, e.g., hospital
days and VAS measurements, the difference between
the groups will initially be examined using two sample
t-tests and further adjustments will be made for minimisation variables. Subsequent analyses will consider
the repeated VAS scores measured on the same patient
and missing VAS scores (assuming that missing scores
are missing at random) and will include a time by treatment interaction term along with random intercepts
and time effects as appropriate. An interim analysis is
planned after the recruitment and follow-up of 60–80
participants.
The research team will document as accurately as possible the reasons for any non-completion or missing data,
thereby minimising truly absent data. The expected dropout rate from patient death has been factored into the
power calculation and is based on survival figures and
previous studies.

The study is sponsored by the Institute for Respiratory
Research a not-for-profit organisation.
Contact details: Mr Bi Lam, Finance Manager, Level 2,
6 Verdun Street, Nedlands WA 6009
t| +61 8 6151 0877 e| bi.lam@resphealth.uwa.edu.au
The study investigators/institutions will permit trialrelated monitoring, audits, and regulatory inspections,
providing direct access to source data/documents. This
may include, but is not limited to, review by external
sponsors, Human Research Ethics Committees, and
institutional governance review bodies.

Ethics

The trial has been approved by an ethics committee for
all sites (see declarations). The investigators will receive
approval from the ethics committee for any amendment
to the protocol and ensure it is signed by any patient
subsequently entering the trial and those currently in
the study, if affected by the amendment.
Trial monitoring and oversight

The trial steering committee (TSC) will be responsible for the supervision of the trial in all its aspects,
including completion of the trial to clinical and ethical standards. Members of the TSC include the principal investigator, selected investigators from each site,
external independent members, a consumer representative, and the trial coordinator.
The data safety and monitoring board (DSMB) will
ensure the safety of study participants through monitoring of ethical conduct of the study and adverse
events and consider new data (recently published studies) that may determine the validity of study continuation. The DSMB includes an independent chairperson
and other independent members, one of whom is a
statistician.

Adverse event reporting and harms

Although both arms of this study involve procedures that are standard of care, participants will be
carefully monitored for the development of adverse
events, which will be documented according to standard “Adverse Event Reporting”. Any serious adverse
events, whether related to the intervention or not, will
be reported, documented, and reported to the DSMB.
Adverse events will be followed up until resolution or
documented as not resolved on the adverse event log at
study completion.
All deaths, anticipated or unanticipated, will be discussed with the DSMB. The committee determines
whether significant benefits or risks have been uncovered which may have an impact on the feasibility and/or
ethical conduct of the study. The DSMB will also help
to ensure the scientific integrity of the study by reviewing the quality of the data it uses to make its decisions.
Plans for dissemination

It is expected that the study results will be published in
a peer-reviewed journal. Presentations at national and
international conferences are anticipated.

Discussion
IPC and VATS are both well-established treatments for
MPE, but the choice of procedure is often dictated by
clinician bias and available resources. The results of this
study will provide the first objective evidence-based
guidance on which treatment would be the best for
patients who are suitable for both interventions.
Trial status
Protocol version: Version 3.00/4.02.19
Date recruitment began: 23 April 2019
Estimated recruitment completion date: 31 December 2024

Fitzgerald et al. Trials

(2022) 23:530

Abbreviations
ASA: American Society of Anaesthesiologists score; CXR: Chest x-ray; DSMB:
Data and Safety Monitoring Board; ECOG: Eastern Cooperative Oncology
Group; IPC: Indwelling pleural catheter; MPE: Malignant pleural effusions; QoL:
Quality of life; SAE: Serious adverse event; TSC: Trial Steering Committee; VAS:
Visual analogue scale; VATS: Video-assisted thoracoscopic surgery.

Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13063-022-06405-7.
Additional file 1. Standard Operating Procedure AMPLE-3 Trial: Diagnos‑
ing Trapped Lung.
Authors’ contributions
Conceptualisation: DBF, YCGL; data curation: DBF, CS, ALT; formal analysis: KM,
CB, YCGL; funding acquisition: DBF, CS, YCGL; data collection/enrolment: DBF,
CS, ALT, BK, NS, ETF, TS, SM, RS, AB, PN, AB, JG, MW, JMD, GW, PS, KC, KY; meth‑
odology: DBF, YCGL, NAM, DFK, KY; project administration: ALT, CAR; resources:
YCGL; supervision: YCGL, NAM, DFK, KY; protocol preparation (original draft):
DBF, CS, YCGL; all authors reviewed and approved final submission.
Funding
This study is supported by a project grant for the New South Wales Dust
Disease Board (2018–2021) and the National Health and Medical Research
Council (NHMRC, 2021–2025). DBF received a clinical research fellowship from
the Western Australia Cancer and Palliative Care Network and a long-term
research fellowship from the European Respiratory Society. ETF received
an NHMRC early career fellowship. YCGL is a Medical Research Future Fund
Practitioner Fellow and has received project grant funding from the NHMRC,
Sir Charles Gairdner Research Advisory Committee, and New South Wales Dust
Disease Board.
None of the funding bodies have a direct role in study design, data collection,
and analysis or report writing and publication.
Availability of data and materials
The research team at the lead site will have access to the final trial dataset.
Supporting data including standard operating procedures, details of data
management procedures, case report forms, and datasets generated and/or
analysed during the current study will be available to the scientific community
with as few restrictions as possible, while retaining exclusive use until publica‑
tion of major outcomes. Data requests from qualified researchers should be
made to YCGL (gary.lee@uwa.edu.au).

Declarations
Ethics approval and consent to participate
The trial has been approved by the Sir Charles Gairdner and Osborne Park
Health Care Group (HREC) for WA Health hospitals, Northern and St Vincent’s
(Melbourne) Hospitals, Victoria; Royal Adelaide Hospital, South Australia; St
George, Westmead, John Hunter, the Sutherland and Concord Repatriation
General Hospitals, New South Wales; Sunshine Coast University and The
Prince Charles Hospitals, Queensland; University Health Network Research
Ethics Board for Toronto General Hospital, Canada; St John of God Health Care
Human Research Ethics Committee for Midland and Murdoch Hospitals, West‑
ern Australia; Health and Disability Ethics Committees for Wellington Hospital,
New Zealand; Hollywood Private Hospital Research Ethics Committee for Hol‑
lywood Private Hospital, WA. All participants will sign a consent form prior to
enrolment in the study, including consent for publication of the anonymised
data. A model consent form is available on request.
Competing interests
Rocket Medical (UK) Plc has provided free drainage kits and an unrestricted
educational grant for previous clinical trials led by YCGL but was not involved
in the conception, design, or management of the study, the protocol, the
statistical analysis, or the plan for dissemination. NAM reports grants from BD
Carefusion, personal fees from BD Carefusion, and personal fees from Cook
Medical, outside the submitted work.

Page 8 of 9

Author details
1
Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
2
Medical School, Faculty of Health & Medical Sciences, University of Western
Australia, Perth, WA, Australia. 3 Pleural Medicine Unit, Institute for Respiratory
Health, Perth, WA, Australia. 4 School of Medical and Health Sciences, Edith
Cowan University, Joondalup, WA, Australia. 5 School of Population and Global
Health, University of Western Australia, Perth, WA, Australia. 6 Department
of Respiratory and Sleep Medicine, The Sutherland Hospital, Sydney, NSW,
Australia. 7 University of New South Wales, Sydney, NSW, Australia. 8 Respiratory
Department, Wellington Regional Hospital, Wellington, New Zealand. 9 Res‑
piratory Medicine, St John of God Hospital Midland, Midland, WA, Australia.
10
Respiratory Medicine, Northern Health, Epping, VIC, Australia. 11 Respiratory
Medicine, Concord Repatriation General Hospital, Concord West, NSW, Aus‑
tralia. 12 Faculty of Medicine and Health Sciences, Macquarie University, Syd‑
ney, NSW, Australia. 13 Respiratory Medicine, Fiona Stanley Hospital, Murdoch,
WA, Australia. 14 Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA,
Australia. 15 Adelaide Medical School, Faculty of Health and Medical Science,
University of Adelaide, Adelaide, SA, Australia. 16 Thoracic Medicine, The Prince
Charles Hospital, Brisbane, QLD, Australia. 17 School of Medicine, The University
of Queensland School of Medicine, Brisbane, QLD, Australia. 18 Respiratory
Department, Sunshine Coast University Hospital, Birtinya, QLD, Australia.
19
Griffith University, Brisbane, QLD, Australia. 20 Thoracic Surgery, The Prince
Charles Hospital, Brisbane, QLD, Australia. 21 Respiratory and Sleep Medicine
Department, St Vincent’s Hospital, Melbourne, VIC, Australia. 22 Department
of Cardiothoracic Surgery & University of Melbourne Department of Surgery,
St Vincent’s Hospital, Melbourne, VIC, Australia. 23 Division of Thoracic Surgery,
Toronto General Hospital University Health Network, University of Toronto,
Toronto, Ontario, Canada. 24 Guy’s and St Thomas’ NHS Foundation Trust, Lon‑
don, UK. 25 Department of Medicine, Johns Hopkins University, Baltimore, MD,
USA. 26 Academic Respiratory Unit, Bristol Medical School, University of Bristol,
Bristol, UK.
Received: 6 January 2022 Accepted: 16 May 2022

References
1. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion
in a well-defined region. Epidemiologic study in central Bohemia. Chest.
1993;104(5):1486–9.
2. van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diag‑
nosis and treatment of malignant pleural mesothelioma. J Thorac Dis.
2013;5(6):E254–307.
3. Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant
pleural effusions: data from the 2012 national inpatient sample. Chest.
2017;151(4):845–54.
4. Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant
pleural effusion: development and validation of the LENT prognostic
score. Thorax. 2014;69(12):1098–104.
5. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival
for patients with malignant pleural effusions. Chest. 2000;117(1):79–86.
6. Fysh ET, Waterer GW, Kendall PA, et al. Indwelling pleural catheters reduce
inpatient days over pleurodesis for malignant pleural effusion. Chest.
2012;142(2):394–400.
7. Mack MJ, Aronoff RJ, Acuff TE, Douthit MB, Bowman RT, Ryan WH. Present
role of thoracoscopy in the diagnosis and treatment of diseases of the
chest. Ann Thorac Surg. 1992;54(3):403–8.
8. Scarci M, Caruana E, Bertolaccini L, et al. Current practices in the manage‑
ment of malignant pleural effusions: a survey among members of the
European Society of Thoracic Surgeons. Interact Cardiovasc Thorac Surg.
2017;24(3):414–7.
9. Hunt BM, Farivar AS, Vallieres E, et al. Thoracoscopic talc versus tunneled
pleural catheters for palliation of malignant pleural effusions. Ann Thorac
Surg. 2012;94(4):1053–7.
10. Barbetakis N, Asteriou C, Papadopoulou F, et al. Early and late morbidity
and mortality and life expectancy following thoracoscopic talc insuffla‑
tion for control of malignant pleural effusions: a review of 400 cases. J
Cardiothorac Surg. 2010;5:27.
11. Schulze M, Boehle AS, Kurdow R, Dohrmann P, Henne-Bruns D. Effective
treatment of malignant pleural effusion by minimal invasive thoracic

Fitzgerald et al. Trials

12.
13.
14.
15.
16.
17.

18.
19.
20.
21.
22.

23.

24.
25.

26.
27.
28.
29.

30.
31.
32.
33.

(2022) 23:530

surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in
101 patients. Ann Thorac Surg. 2001;71(6):1809–12.
Trotter D, Aly A, Siu L, Knight S. Video-assisted thoracoscopic (VATS)
pleurodesis for malignant effusion: an Australian teaching hospital’s
experience. Heart Lung Circ. 2005;14(2):93–7.
Fysh ET, Tan SK, Read CA, et al. Pleurodesis outcome in malignant pleural
mesothelioma. Thorax. 2013;68(6):594–6.
Arapis K, Caliandro R, Stern JB, Girard P, Debrosse D, Gossot D. Thoraco‑
scopic palliative treatment of malignant pleural effusions: results in 273
patients. Surg Endosc. 2006;20(6):919–23.
Cardillo G, Facciolo F, Carbone L, et al. Long-term follow-up of videoassisted talc pleurodesis in malignant recurrent pleural effusions. Eur J
Cardiothorac Surg. 2002;21(2):302–5.
Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of
talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest.
2005;127(3):909–15.
Medford AR, Awan YM, Marchbank A, Rahamim J, Unsworth-White J,
Pearson PJ. Diagnostic and therapeutic performance of video-assisted
thoracoscopic surgery (VATS) in investigation and management of pleu‑
ral exudates. Ann R Coll Surg Engl. 2008;90(7):597–600.
Yoon DW, Cho JH, Choi YS, et al. Predictors of survival in patients who
underwent video-assisted thoracic surgery talc pleurodesis for malignant
pleural effusion. Thorac Cancer. 2016;7(4):393–8.
Laisaar T, Palmiste V, Vooder T, Umbleja T. Life expectancy of patients with
malignant pleural effusion treated with video-assisted thoracoscopic talc
pleurodesis. Interact Cardiovasc Thorac Surg. 2006;5(3):307–10.
Marrazzo A, Noto A, Casa L, et al. Video-thoracoscopic surgical pleurode‑
sis in the management of malignant pleural effusion: the importance of
an early intervention. J Pain Symptom Manage. 2005;30(1):75–9.
Bayman EO, Parekh KR, Keech J, Selte A, Brennan TJ. A prospec‑
tive study of chronic pain after thoracic surgery. Anesthesiology.
2017;126(5):938–51.
Thomas R, Fysh ETH, Smith NA, et al. Effect of an indwelling pleural
catheter vs talc pleurodesis on hospitalization days in patients with
malignant pleural effusion: the AMPLE Randomized Clinical Trial. JAMA.
2017;318(19):1903–12.
Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural cath‑
eter vs chest tube and talc pleurodesis for relieving dyspnea in patients
with malignant pleural effusion: the TIME2 randomized controlled trial.
JAMA. 2012;307(22):2383–9.
Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of
indwelling pleural catheter and doxycycline pleurodesis in the manage‑
ment of malignant pleural effusions. Cancer. 1999;86(10):1992–9.
Efthymiou CA, Masudi T, Thorpe JA, Papagiannopoulos K. Malignant
pleural effusion in the presence of trapped lung. Five-year experi‑
ence of PleurX tunnelled catheters. Interact Cardiovasc Thorac Surg.
2009;9(6):961–4.
Qureshi RA, Collinson SL, Powell RJ, Froeschle PO, Berrisford RG. Man‑
agement of malignant pleural effusion associated with trapped lung
syndrome. Asian Cardiovasc Thorac Ann. 2008;16(2):120–3.
Tremblay A, Michaud G. Single-center experience with 250 tunnelled
pleural catheter insertions for malignant pleural effusion. Chest.
2006;129(2):362–8.
Wahidi MM, Reddy C, Yarmus L, et al. Randomized trial of pleural fluid
drainage frequency in patients with malignant pleural effusions. The
ASAP Trial. Am J Respir Crit Care Med. 2017;195(8):1050–7.
Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus
symptom-guided drainage of malignant pleural effusion via indwell‑
ing pleural catheters (AMPLE-2): an open-label randomised trial. Lancet
Respir Med. 2018;6(9):671–80.
Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malig‑
nant pleural effusions: a pilot study. Chest. 2011;139(6):1419–23.
Ahmed L, Ip H, Rao D, Patel N, Noorzad F. Talc pleurodesis through
indwelling pleural catheters for malignant pleural effusions: retrospective
case series of a novel clinical pathway. Chest. 2014;146(6):e190–4.
Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient talc administration
by indwelling pleural catheter for malignant effusion. N Engl J Med.
2018;378(14):1313–22.
Fysh ET, Tremblay A, Feller-Kopman D, et al. Clinical outcomes of
indwelling pleural catheter-related pleural infections: an international
multicenter study. Chest. 2013;144(5):1597–602.

Page 9 of 9

34. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled
pleural catheters in adults with malignant pleural effusions: a systematic
review. J Gen Intern Med. 2011;26(1):70–6.
35. Thomas R, Piccolo F, Miller D, et al. Intrapleural fibrinolysis for the treat‑
ment of indwelling pleural catheter-related symptomatic loculations: a
multicenter observational study. Chest. 2015;148(3):746–51.
36. Thomas R, Budgeon CA, Kuok YJ, et al. Catheter tract metastasis associ‑
ated with indwelling pleural catheters. Chest. 2014;146(3):557–62.
37. Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx
catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med.
2010;13(1):59–65.
38. Puri V, Pyrdeck TL, Crabtree TD, et al. Treatment of malignant pleural
effusion: a cost-effectiveness analysis. Ann Thorac Surg. 2012;94(2):374–9
discussion 379-380.
39. Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Compar‑
ing cost of indwelling pleural catheter vs talc pleurodesis for malignant
pleural effusion. Chest. 2014;146(4):991–1000.
40. Azzopardi M, Thomas R, Muruganandan S, et al. Protocol of the
Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre
randomised study of aggressive versus symptom-guided drainage via
indwelling pleural catheters. BMJ Open. 2016;6(7):e011480.
41. Jeffery E, Lee YG, McVeigh J, et al. Feasibility of objectively measured
physical activity and sedentary behavior in patients with malignant
pleural effusion. Support Care Cancer. 2017. [Epub ahead of print].

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.

Ready to submit your research ? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions

